# Ryoncil (ryoncil) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ryoncil

> The FDA approved Ryoncil (ryoncil), sponsored by MESOBLAST LTD (MESO), on June 30, 2025 for SR-aGVHD in December 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Ryoncil (ryoncil) FDA approved?

Yes. The FDA approved Ryoncil (ryoncil), sponsored by MESOBLAST LTD (MESO), on June 30, 2025 for SR-aGVHD in December 2024. Press release filed with the SEC (EX-99): "Selling, marketing and distribution increased by $11.4 million from $4.7 million for the year ended June 30, 2025 to $16.1 million for the year ended June 30, 2026 primarily due to increased commercial activities for Ryoncil® following FDA approval of the product for the treatment of pediatric SR-aGVHD in December 2024." [Calendar and source filings](https://sec-api.dev/pdufa/ryoncil)

Source: Press release filed with the SEC (EX-99), accession 0001345099-26-000087, https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm (retrieved 2026-11-12). Last confirmed 2026-10-13. Cite: https://sec-api.dev/pdufa/ryoncil#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ryoncil (ryoncil) |
| Codes |  |
| Sponsor | MESOBLAST LTD (MESO) https://sec-api.dev/companies/meso/catalysts |
| Indications | [children with sr-agvhd](https://sec-api.dev/indications/children-with-sr-agvhd), sr-agvhd in children 2 months and older, sr-agvhd in december 2024, children with sragvhd, sr- agvhd in children 2 months and older, sr-agvhd in pediatric patients |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 8, 2024: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2024-11-18, last confirmed 2025-10-28.
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "In July 2024, the Group resubmitted its Biologics License Application ("BLA") with the U.S. Food and Drug Administration ("FDA") for approval of Ryoncil® for the treatment of pediatric patients with steroid-refractory acute graft versus host disease ("SR-aGvHD")." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-24-000079): "19 m e s o b l a s t Mesoblast resubmitted its Biologics License Application (BLA) to FDA for approval of RYONCIL on July 8, 2024 and anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025." https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm

### September 30, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-18, last confirmed 2024-11-18.
- Press release filed with the SEC (EX-99) (accession 0001345099-24-000079): "11 m e s o b l a s t Cash balance at September 30, 2024 is US$51.1 million, with additional US$60.0 million available from existing financing facilities on FDA approval of RYONCIL." https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm

### December 18, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: SR-aGvHD in children 2 months and older.
- First seen 2025-02-28, last confirmed 2026-10-13.
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "Ryoncil® was approved by the FDA on December 18, 2024 as the first MSC therapy in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "Ryoncil® was approved by the FDA on December 18, 2024 as the first MSC therapy in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "In December 2024, the FDA approved Mesoblast's Ryoncil® for the treatment of pediatric SR- aGvHD in children 2 months and older." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "The fair value remeasurement of contingent consideration also includes the remeasurement of the milestone paid in relation to the FDA approval of Ryoncil® in the treatment of children with SR-aGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "In December 2024, the FDA approved Ryoncil® for the treatment of SR-aGVHD in pediatric patients." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "This amount relates to the amortization of our MSC assets, which began following the FDA approval of Ryoncil® for the treatment of pediatric SR-aGVHD in December 2024, upon which our MSC assets were reclassified from in-process research and development ("IPRD") acquired to current marketed products." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "The increase is primarily due to a reversal of $23.0 million in December 2024 in relation to the provision against the carrying value of pre-launch inventory as a result of FDA approval of Ryoncil® for pediatric SR-aGVHD during the year ended June 30, 2025." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "Within the $14.9 million loss, the Group also recognized a loss of $10.3 million due to the remeasurement of the milestone paid in relation to the FDA approval of Ryoncil® in the treatment of children with SRaGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "These amounts were recorded in revenue as there are no further performance obligations required in regards to these items. (ii) Revenue from product sales In December 2024, the FDA approved Mesoblast's Ryoncil® for the treatment of pediatric SR-aGvHD in children 2 months and older." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "In December 2024, the FDA approved Mesoblast's Ryoncil® for the treatment of SR-aGvHD in children 2 months and older." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "Completed a global private placement primarily to existing major US, UK, and Australian shareholders raising approximately US$160.0 million (A$260 million) December 2024 The FDA approved Ryoncil® as the first mesenchymal stromal cell (MSC) therapy in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "In December 2024, the FDA approved Mesoblast's Ryoncil® for the treatment of pediatric SR- aGvHD in children 2 months and older." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm

### Jan 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: children with SR-aGVHD.
- First seen 2025-10-28, last confirmed 2026-10-13.
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "In January 2025, we issued 10,228,239 ordinary shares to Osiris as payment for a $20.0 million milestone following the FDA approval of Ryoncil® in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "(5) In January 2025, 10,228,239 ordinary shares were issued at A$3.15 per share as payment for a $20 million milestone within contingent consideration recognized on the balance sheet following the FDA approval of Ryoncil® in the treatment of children with SR-aGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "In January 2025, we issued 10,228,239 ordinaryy shares to Osiris as payment for a $20.0 million milestone following the FDA approval of Ryoncil® in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "In January 2025, we issued 10,228,239 ordinary shares to Osiris as payment for a $20.0 million milestone following the FDA approval of Ryoncil® in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "In January 2025, the Group issued 10,228,239 ordinary shares as payment for a $20.0 million milestone within contingent consideration following the FDA approval of Ryoncil® in the treatment of children with SR-aGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "(2) In January 2025, the Group issued 10,228,239 ordinary shares as payment for a $20.0 million milestone within contingent consideration following the FDA approval of Ryoncil® in the treatment of children with SR-aGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "(4) In January 2025, 10,228,239 ordinary shares were issued at A$3.15 per share as payment for a $20 million milestone within contingent consideration recognized on the balance sheet following the FDA approval of Ryoncil® in the treatment of children with SR-aGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- SEC Form 10-K (accession 0001345099-26-000081): "In January 2025, we issued 10,228,239 ordinary shares to Osiris as payment for a $20.0 million milestone following the FDA approval of Ryoncil® in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/meso-20260630.htm

### January 7, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-18, last confirmed 2025-10-28.
- Press release filed with the SEC (EX-99) (accession 0001345099-24-000079): "19 m e s o b l a s t Mesoblast resubmitted its Biologics License Application (BLA) to FDA for approval of RYONCIL on July 8, 2024 and anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025." https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "FDA considered the resubmission to be a complete response and set a Prescription Drug User Fee Act ("PDUFA") goal date of January 7, 2025." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- SEC Form 10-K (accession 0001345099-25-000067): "FDA considered the resubmission to be a complete response and set a Prescription Drug User Fee Act ("PDUFA") goal date of January 7, 2025." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000067/meso-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "Ryoncil® was approved by the FDA on December 18, 2024 as the first MSC therapy in the United States." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm

### March 28, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: SR-aGVHD in December 2024, as well.
- First seen 2025-07-18, last confirmed 2026-10-13.
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "the full annual impairment assessment performed by the Group at March 31, 2025, including the impact of the FDA approval of Ryoncil® for the treatment of pediatric SR-aGVHD in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000058): "Ryoncil® is the first and only FDA approved mesenchymal stromal cell (MSC) product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000058/exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "The increase is due to the commencement of product sales of Ryoncil® in March 2025 following FDA approval of the product for the treatment of pediatric SR-aGVHD in December 2024, as well as the related amortization of current marketed products." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "The increase is due to the commencement of product sales of Ryoncil® in March 2025 following FDA approval of the product for the treatment of pediatric SR-aGVHD in December 2024, as well as the related amortization of current marketed products." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm

### June 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: SR-aGVHD in December 2024.
- First seen 2025-08-29, last confirmed 2026-10-13.
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "Selling, marketing and distribution increased by $11.4 million from $4.7 million for the year ended June 30, 2025 to $16.1 million for the year ended June 30, 2026 primarily due to increased commercial activities for Ryoncil® following FDA approval of the product for the treatment of pediatric SR-aGVHD in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-26-000087): "Within the $14.9 million loss for the year ended June 30, 2025, we recognized a loss of $10.3 million due to the remeasurement of the milestone paid in relation to the FDA approval of Ryoncil® in the treatment of children with SRaGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "Amortization of current marketed products decreased by $1.5 million in the year ended June 30, 2025, compared with the year ended June 30, 2024 due to the reclassification of amortization related to our MSC assets from research and development expenses to cost of revenues following the FDA approval of Ryoncil® for the treatment of pediatric SR- aGVHD in December 2024. 87" https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "Selling, marketing and distribution increased by $4.0 million for the year ended June 30, 2025 compared with the year ended June 30, 2024 primarily due to increased commercial activities for Ryoncil® following FDA approval of the product for the treatment of pediatric SR-aGVHD in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "Legal and professional fees increased by $2.0 million for the year ended June 30, 2025 compared with the year ended June 30, 2024 primarily due to expenses incurred related to the FDA approval of Ryoncil® for pediatric SR-aGVHD during the year ended June 30, 2025." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- Press release filed with the SEC (EX-99) (accession 0001345099-25-000090): "Within the $14.9 million loss for the year ended June 30, 2025, we also recognized a loss of $10.3 million due to the remeasurement of the milestone paid in relation to the FDA approval of Ryoncil® in the treatment of children with SR- aGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm
- SEC Form 10-K (accession 0001345099-26-000081): "Within the $14.9 million loss for the year ended June 30, 2025, we recognized a loss of $10.3 million due to the remeasurement of the milestone paid in relation to the FDA approval of Ryoncil® in the treatment of children with SRaGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/meso-20260630.htm
- SEC Form 10-K (accession 0001345099-25-000067): "Amortization of current marketed products decreased by $1.5 million in the year ended June 30, 2025, compared with the year ended June 30, 2024 due to the reclassification of amortization related to our MSC assets from research and development expenses to cost of revenues following the FDA approval of Ryoncil® for the treatment of pediatric SR-aGVHD in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000067/meso-20250630.htm
- SEC Form 10-K (accession 0001345099-25-000067): "Within the $14.9 million loss for the year ended June 30, 2025, we also recognized a loss of $10.3 million due to the remeasurement of the milestone paid in relation to the FDA approval of Ryoncil® in the treatment of children with SR-aGVHD in the United States in December 2024." https://www.sec.gov/Archives/edgar/data/1345099/000134509925000067/meso-20250630.htm

## Same indication

- [Remestemcel](https://sec-api.dev/pdufa/remestemcel) (MESO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ryoncil.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ryoncil (ryoncil) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ryoncil

```bibtex
@misc{secapidev_pdufa_ryoncil_20261116,
  title        = {Ryoncil (ryoncil) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ryoncil}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ryoncil_20261116","title":"Ryoncil (ryoncil) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ryoncil","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
